Amdocs Limited Announces Pricing of Public Offering.ST. LOUIS--(BUSINESS WIRE)--Oct. 7, 1999-- Amdocs Limited (NYSE NYSE See: New York Stock Exchange :DOX DOX Design of Experiments DOX Direct Operational Exchange ) today announced that the offering of 18 million of its ordinary shares by Amdocs International Limited (AIL AIL 1. Angiocentric immunoproliferative lesion 2. Angioimmunoblastic lymphadenopathy ), a shareholder in Amdocs Limited, was priced at $24.25 per share. All of the offered shares were sold by AIL, a private investment company beneficially owned by Morris Kahn. Underwriters for the offering include Goldman, Sachs & Co., Banc of America Securities LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , Deutsche Banc Alex. Brown, Lehman Brothers, and Prudential Securities. Copies of the final prospectus Final Prospectus A legal document stating the price of a newly issued security, the delivery date, and other facts that are important for investors. Notes: The final prospectus must be given to every investor who purchases a new issue of registered securities. for the offering may be obtained from Goldman, Sachs & Co., Prospectus Department, 85 Broad Street, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , New York 10004. Amdocs is a leading provider of product-driven information system solutions to premier telecommunications companies worldwide. Amdocs has an unparalleled success record in project delivery of its mission-critical products. With human resources of over 4,300 information systems professionals dedicated to the telecommunications industry, Amdocs has an installed base of successful projects with more than 70 major telecommunications companies throughout the world. For more information visit our Web site at www.amdocs.com. This press release may contain forward-looking statements as defined under the Securities Act of 1933, as amended. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the adverse effects of market competition, rapid changes in technology that may make the company's products and services less competitive, potential loss of major customers, and risks associated with operating businesses in the international market. These and other risks are discussed at greater length in the Company's filings with the Securities and Exchange Commission. |
|
||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion